Evaluation of Reasons for Discontinuation of Atropine 0.01% in Myopia Management: A Single-Center Retrospective Study from Türkiye.

Abstract

Objectives: This study aimed to identify the key factors contributing to non-adherence in patients using 0.01% atropine for progressive myopia control in a specific single-center Turkish population and to propose strategies to enhance adherence.

Materials and methods: This retrospective study included 30 patients (mean age: 10.67±3.47 years; age range: 5-16 years; 14 males and 16 females) diagnosed with progressive myopia and prescribed 0.01% atropine treatment in our clinic between January and June 2021. All participants had discontinued 0.01% atropine treatment before completion. The reasons for discontinuation were analyzed using patient records and categorized into factors such as light sensitivity, difficulties with near vision, ocular or systemic side effects, the need for monthly eye drop renewal, and the long treatment duration. Data on patients' age, sex, treatment adherence, and reasons for discontinuation were collected. Statistical analyses were performed using IBM SPSS Statistics software.

Results: The treatment discontinuation rate in our patient population was 14.92% (95% confidence interval: 10.23-19.61). The most common reasons for discontinuation were the need for monthly drop renewal (80%), long treatment duration (70%), and light sensitivity (60%). Discontinuation rates did not significantly differ by age group (p>0.05). The need for monthly renewal was more frequently reported as a barrier among female patients. Informed consent procedures had highlighted the long treatment duration and the need for monthly renewal, but these still represented barriers to adherence for some families.

Conclusion: To improve adherence to 0.01% atropine treatment for progressive myopia in our patient population, patient education and enhanced support systems are essential. Implementing strategies to address challenges related to monthly renewal and providing better information about the long-term benefits of treatment could help increase adherence rates.